C41No association between prenatal PrEP exposure and adverse growth outcomes among Kenyan infants: a prospective studyE-posterPrEP and pregnant women
B59No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trialE-posterPharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations
B37NNRTI MK-8507 does not alter the pharmacokinetics of the combined oral contraceptive levonorgestrel/ethinyl estradiolE-posterDrug interactions
C32Next generation 3D-printed intravaginal rings for prevention of HIV and unplanned pregnancyE-posterNovel delivery systems (e.g., rings, implants, transdermal systems)
B45New generation of HYBRID CAR-T cells efficiently kill HIV infected cells and neutralize cell-free virusOn-demand oral abstract sessionImmune-based therapy trials
A6Neutralizing antibody induction associated with a germline immunoglobulin gene polymorphism in rhesus macaques after neutralization-resistant SIVsmE543-3 infectionE-posterHumoral immunity (including broadly neutralizing antibodies)
B67Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trialOn-demand oral abstract sessionMental health and neurocognition in paediatric and adolescent populations
C41Navigating PrEP use and pregnancy: perspectives among adolescent girls and young women (AGYW) in Tshwane, South AfricaE-posterPrEP and pregnant women
A18Naive infection predicts HIV reservoir size and diversity in individuals with a spectrum of immunological controlE-posterCellular and tissue reservoirs of HIV/SIV
A18Naïve CD4+ T cells form the bulk of the translation competent HIV-1 reservoir in vertically infected children and adolescentsOral abstract session with live Q&ACellular and tissue reservoirs of HIV/SIV
321 - 330 of 870 items